Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Loa Loa (eye worm) | MH2 domain-containing protein | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Brugia malayi | MH2 domain containing protein | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Loa Loa (eye worm) | transcription factor SMAD2 | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | TAR-binding protein | 0.0061 | 0.3552 | 0.3552 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0024 | 0.0674 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 0.3552 | 0.5 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0024 | 0.0674 | 0.5 |
Echinococcus multilocularis | tar DNA binding protein | 0.0061 | 0.3552 | 0.5 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0024 | 0.0674 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 0.3552 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 0.3552 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0024 | 0.0674 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 0.3552 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0024 | 0.0674 | 0.5 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 1 | 1 |
Loa Loa (eye worm) | TAR-binding protein | 0.0061 | 0.3552 | 0.3086 |
Brugia malayi | hypothetical protein | 0.0024 | 0.0674 | 0.0674 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0061 | 0.3552 | 0.3552 |
Loa Loa (eye worm) | RNA binding protein | 0.0061 | 0.3552 | 0.3086 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0024 | 0.0674 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0024 | 0.0674 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 0.3552 | 0.5 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 1 | 1 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0061 | 0.3552 | 0.3086 |
Brugia malayi | RNA binding protein | 0.0061 | 0.3552 | 0.3552 |
Echinococcus granulosus | tar DNA binding protein | 0.0061 | 0.3552 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0024 | 0.0674 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 3.5481 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | = 44.6684 um | PUBCHEM_BIOASSAY: qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent). (Class of assay: confirmatory) [Related pubchem assays: 1002 (Confirmation Concentration-Response Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent)), 585 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent) - a screen old NIH MLSMR collection), 584 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent) - a screen of the old NIH MLSMR collection), 1003 (Confirmation Cuvette-Based Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent))] | ChEMBL. | No reference |
Potency (functional) | 125.8925 uM | PubChem BioAssay. qHTS of PTHR Inhibitors: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.